▼ -0.03% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for BioSpecifics Technologies in the last 3 months. The average price target is $88.50, with a high forecast of $88.50 and a low forecast of $88.50. The average price target represents a -0.03% upside from the last price of $88.53.
The current consensus among 1 investment analysts is to hold stock in BioSpecifics Technologies. This Hold consensus rating has held steady for over two years.
BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.